Minireview: RET: Normal and abnormal functions

被引：139

作者：

Santoro, M ^{[1
]}

Melillo, RM ^{[1
]}

Carlomagno, F ^{[1
]}

Vecchio, G ^{[1
]}

Fusco, A ^{[1
]}

机构：

[1] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy

来源：

ENDOCRINOLOGY | 2004年 / 145卷 / 12期

关键词：

D O I：

10.1210/en.2004-0922

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The RET gene encodes a single-pass transmembrane receptor tyrosine kinase. RET is the oncogene that causes papillary thyroid carcinoma and medullary thyroid carcinoma. The latter may arise as a component of multiple endocrine neoplasia type 2 syndromes; germline mutations in RET are responsible for multiple endocrine neoplasia type 2 inheritance. In this report we review data on the mechanisms leading to RET oncogenic conversion and on RET targeting as a strategy in thyroid cancer treatment.

引用

页码：5448 / 5451

页数：4

共 44 条

[1] The GDNF family: Signalling, biological functions and therapeutic value [J].

Airaksinen, MS ;

Saarma, M .

NATURE REVIEWS NEUROSCIENCE, 2002, 3 (05) :383-394

[2] Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas [J].

Bender, BU ;

Gutsche, M ;

Gläsker, S ;

Müller, B ;

Kirste, G ;

Eng, C ;

Neumann, HPH .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12) :4568-4574

[3] Oncogenic kinase signalling [J].

Blume-Jensen, P ;

Hunter, T .

NATURE, 2001, 411 (6835) :355-365

[4] Guidelines for diagnosis and therapy of MEN type 1 and type 2 [J].

Brandi, ML ;

Gagel, RF ;

Angeli, A ;

Bilezikian, JP ;

Beck-Peccoz, P ;

Bordi, C ;

Conte-Devolx, B ;

Falchetti, A ;

Gheri, RG ;

Libroia, A ;

Lips, CJM ;

Lombardi, G ;

Mannelli, M ;

Pacini, F ;

Pondder, BAJ ;

Raue, F ;

Skogseid, B ;

Tamburrano, G ;

Thakker, RV ;

Thompson, NW ;

Tomassetti, P ;

Tonelli, F ;

Wells, SA ;

Marx, SJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5658-5671

[5] Molecular diagnosis of multiple endocrine neoplasia Type 2 [J].

Bugalho, MJ ;

Domingues, R ;

Sobrinho, L .

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2003, 3 (06) :769-779

[6]

Carlomagno F, 2002, CANCER RES, V62, P7284

[7] Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors [J].

Carlomagno, F ;

Guida, T ;

Anaganti, S ;

Vecchio, G ;

Fusco, A ;

Ryan, AJ ;

Billaud, M ;

Santoro, M .

ONCOGENE, 2004, 23 (36) :6056-6063

[8] Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) [J].

Carlomagno, F ;

Vitagliano, D ;

Guida, T ;

Basolo, F ;

Castellone, MD ;

Melillo, RM ;

Fusco, A ;

Santoro, M .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (04) :1897-1902

[9]

Carlomagno F, 2002, CANCER RES, V62, P1077

[10]

Carniti C, 2003, CANCER RES, V63, P2234

← 1 2 3 4 5 →